NanoString Technologies increases throughput of nCounter Analysis System

NanoString Technologies, Inc., a privately held life sciences company marketing a novel digital molecular barcoding technology for detecting and counting large sets of targets in biological samples, today announced that it has increased the throughput of its nCounter® Analysis System by expanding its multiplexing capacity to 800 gene transcripts per reaction. This additional capability allows for the high-resolution analysis of 250 additional targets from the same amount of sample, thereby increasing the efficiency of experiments and enabling researchers to perform studies not feasible using other technologies.

“With the new multiplexing capacity, it's as though you are performing 800 qPCR reactions in a single tube with only four pipetting steps.”

With a growing interest in evaluating complex cellular interactions across large numbers of biological samples, scientists are seeking solutions capable of efficiently analyzing defined sets of targets at very high resolution. The nCounter Analysis System is meeting this need by providing a simple workflow, multiplexing, and direct detection and counting of individual RNA transcripts. The application of this technology to elucidate complex biological systems in cancer, developmental biology and cell signaling is demonstrated in a series of recent journal publications (for more information see: www.nanostring.com/applications/publications/).

"One of the important reasons customers choose the nCounter Analysis System is that it provides gold-standard molecular quantification in a highly multiplexed format, and it is easier to use than other technology platforms," said Brad Gray, President and CEO, NanoString Technologies. "With the new multiplexing capacity, it's as though you are performing 800 qPCR reactions in a single tube with only four pipetting steps."

The nCounter Analysis System is widely used for gene signature validation, translational research, pathway analysis, and validation of microarray and next-generation sequencing. It includes a fully automated Prep Station, a Digital Analyzer, the CodeSet (molecular barcodes) and all reagents needed to perform the analysis. The nCounter System offer protocols starting with as little as 100ng of material from a variety of specimen types including FFPE samples, cell lysate, whole-blood lysate, and total RNA. In addition to solutions for gene expression analysis, custom and off-the-shelf assay panels are available for miRNA profiling and genomic copy number variation detection.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    NanoString Technologies. (2019, June 20). NanoString Technologies increases throughput of nCounter Analysis System. News-Medical. Retrieved on April 24, 2024 from https://www.news-medical.net/news/20100715/NanoString-Technologies-increases-throughput-of-nCounter-Analysis-System.aspx.

  • MLA

    NanoString Technologies. "NanoString Technologies increases throughput of nCounter Analysis System". News-Medical. 24 April 2024. <https://www.news-medical.net/news/20100715/NanoString-Technologies-increases-throughput-of-nCounter-Analysis-System.aspx>.

  • Chicago

    NanoString Technologies. "NanoString Technologies increases throughput of nCounter Analysis System". News-Medical. https://www.news-medical.net/news/20100715/NanoString-Technologies-increases-throughput-of-nCounter-Analysis-System.aspx. (accessed April 24, 2024).

  • Harvard

    NanoString Technologies. 2019. NanoString Technologies increases throughput of nCounter Analysis System. News-Medical, viewed 24 April 2024, https://www.news-medical.net/news/20100715/NanoString-Technologies-increases-throughput-of-nCounter-Analysis-System.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
NanoString receives license from Health Canada to market Prosigna Breast Cancer Prognostic Gene Signature Assay